Twareat Medical Center (TMC), slated for direct listing on the Nomu-Parallel Market, posted SAR 16.1 million in net profit for the first half of 2024, up from SAR 6.5 million in the year-ago period.
The first-half profit rise was driven by a 29% annual increase in the six-month revenues, coupled with the higher gross and operating profit margins.
In addition, EBITDA rose to SAR 17.7 million in H1 2024, from SAR 8 million in H1 2023.
On a biannual basis, the company’s bottom line more than doubled from SAR 7.64 million in H2 2023.
Item | H1 2023 | H1 2024 | Change |
---|---|---|---|
Revenues | 71.70 | 92.23 | 28.6 % |
Gross Income | 23.58 | 35.20 | 49.3 % |
Operating Income | 6.62 | 15.88 | 140.0 % |
Net Income | 6.53 | 16.13 | 147.0 % |
Average Shares | 40.00 | 40.00 | - |
Earnings Per Share before unusual items (Riyals) | 0.16 | 0.40 | 147.0 % |
EPS (Riyals) | 0.16 | 0.40 | 147.0 % |
Item | H2 2023 | H1 2024 | Change |
---|---|---|---|
Revenues | 83.02 | 92.23 | 11.1 % |
Gross Income | 25.55 | 35.20 | 37.8 % |
Operating Income | 9.37 | 15.88 | 69.5 % |
Net Income | 7.64 | 16.13 | 111.1 % |
Average Shares | 40.00 | 40.00 | - |
Earnings Per Share before unusual items (Riyals) | 0.19 | 0.40 | 111.1 % |
EPS (Riyals) | 0.19 | 0.40 | 111.1 % |
Shareholders’ equity amounted to SAR 60.69 million by the end of H1 2024, compared to SAR 44.34 million in H1 2023.
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
H1 2015 | - | - | - | - | - | - |
H2 2015 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
H1 2016 | - | - | - | - | - | - |
H2 2016 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
H1 2017 | - | - | - | - | - | - |
H2 2017 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
H1 2018 | - | - | - | - | - | - |
H2 2018 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
H1 2019 | - | - | - | - | - | - |
H2 2019 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
H1 2020 | - | - | - | - | - | - |
H2 2020 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
H1 2021 | - | - | - | - | - | - |
H2 2021 | - | - | - | - | - | - |
2021 | - | - | - | - | - | - |
H1 2022 | - | - | - | - | - | - |
H2 2022 | - | - | - | - | - | - |
2022 | 149.51 | - | 59.69 | - | 26.92 | - |
H1 2023 | 71.70 | - | 23.58 | - | 6.62 | - |
H2 2023 | 83.02 | - | 25.55 | - | 9.37 | - |
2023 | 154.72 | 3.5 % | 49.13 | (17.7 %) | 15.99 | (40.6 %) |
H1 2024 | 92.23 | 28.6 % | 35.20 | 49.3 % | 15.88 | 140.0 % |
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
2014 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
2021 | - | - | - | - | - | - |
2022 | 149.51 | - | 59.69 | - | 26.92 | - |
2023 | 154.72 | 3.5 % | 49.13 | (17.7 %) | 15.99 | (40.6 %) |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | Earnings Per Share before unusual items |
---|---|---|---|---|---|---|
H1 2015 | - | - | - | - | - | - |
H2 2015 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
H1 2016 | - | - | - | - | - | - |
H2 2016 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
H1 2017 | - | - | - | - | - | - |
H2 2017 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
H1 2018 | - | - | - | - | - | - |
H2 2018 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
H1 2019 | - | - | - | - | - | - |
H2 2019 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
H1 2020 | - | - | - | - | - | - |
H2 2020 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
H1 2021 | - | - | - | - | - | - |
H2 2021 | - | - | - | - | - | - |
2021 | - | - | - | - | - | - |
H1 2022 | - | - | - | - | - | - |
H2 2022 | - | - | - | - | - | - |
2022 | 25.43 | - | 0.64 | - | 25.43 | 0.64 |
H1 2023 | 6.53 | - | 0.16 | - | 6.53 | 0.16 |
H2 2023 | 7.64 | - | 0.19 | - | 7.64 | 0.19 |
2023 | 14.17 | (44.3 %) | 0.35 | - | 14.17 | 0.35 |
H1 2024 | 16.13 | 147.0 % | 0.40 | - | 16.13 | 0.40 |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | Earnings Per Share before unusual items |
---|---|---|---|---|---|---|
2014 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
2021 | - | - | - | - | - | - |
2022 | 25.43 | - | 0.64 | - | 25.43 | 0.64 |
2023 | 14.17 | (44.3 %) | 0.35 | - | 14.17 | 0.35 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
H1 2015 | - | - | - |
H2 2015 | - | - | - |
2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
2021 | - | - | - |
H1 2022 | - | - | - |
H2 2022 | - | - | - |
2022 | 39.92 % | 19.05 % | 17.01 % |
H1 2023 | - | - | - |
H2 2023 | 31.75 % | 12.35 % | 9.16 % |
2023 | 31.75 % | 12.35 % | 9.16 % |
H1 2024 | 34.67 % | 16.45 % | 13.56 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
2014 | - | - | - |
2015 | - | - | - |
2016 | - | - | - |
2017 | - | - | - |
2018 | - | - | - |
2019 | - | - | - |
2020 | - | - | - |
2021 | - | - | - |
2022 | 39.92 % | 19.05 % | 17.01 % |
2023 | 31.75 % | 12.35 % | 9.16 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
H1 2015 | - | - | - |
H2 2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
H1 2022 | - | - | - |
H2 2022 | - | - | - |
H1 2023 | 32.88 % | 11.18 % | 9.11 % |
H2 2023 | 30.77 % | 13.36 % | 9.20 % |
H1 2024 | 38.17 % | 19.22 % | 17.49 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
---|---|---|---|---|
H1 2015 | - | - | - | - |
H2 2015 | - | - | - | - |
H1 2016 | - | - | - | - |
H2 2016 | - | - | - | - |
H1 2017 | - | - | - | - |
H2 2017 | - | - | - | - |
H1 2018 | - | - | - | - |
H2 2018 | - | - | - | - |
H1 2019 | - | - | - | - |
H2 2019 | - | - | - | - |
H1 2020 | - | - | - | - |
H2 2020 | - | - | - | - |
H1 2021 | - | - | - | - |
H2 2021 | - | - | - | - |
H1 2022 | - | - | - | - |
H2 2022 | - | - | - | - |
H1 2023 | 40.00 | - | - | 1.11 |
H2 2023 | 40.00 | 0.35 | 0.35 | 1.29 |
H1 2024 | 40.00 | 0.59 | 0.59 | 1.52 |
Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
---|---|---|---|---|
2014 | - | - | - | - |
2015 | - | - | - | - |
2016 | - | - | - | - |
2017 | - | - | - | - |
2018 | - | - | - | - |
2019 | - | - | - | - |
2020 | - | - | - | - |
2021 | - | - | - | - |
2022 | 40.00 | 0.64 | 0.64 | 1.18 |
2023 | 40.00 | 0.35 | 0.35 | 1.29 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
H1 2015 | - | - | - |
H2 2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
H1 2022 | - | - | - |
H2 2022 | - | - | - |
H1 2023 | - | - | - |
H2 2023 | - | - | - |
H1 2024 | - | - | - |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
2014 | - | - | - |
2015 | - | - | - |
2016 | - | - | - |
2017 | - | - | - |
2018 | - | - | - |
2019 | - | - | - |
2020 | - | - | - |
2021 | - | - | - |
2022 | - | - | - |
2023 | - | - | - |
Q2 2024
2024
Period | Rural Area Unit | Industrial Services Unit | Medical Operations Department | Tawreat Medical Center |
---|---|---|---|---|
Q2 2023 | 44.62 | 18.23 | 8.81 | 0.04 |
Q4 2023 | 8.32 | 21.71 | 52.87 | 0.12 |
Q2 2024 | 57.90 | 21.18 | 9.56 | 3.59 |
Period | Rural Area Unit | Industrial Services Unit | Medical Operations Department | Tawreat Medical Center |
---|---|---|---|---|
2022 | 75.11 | 47.59 | 26.81 | - |
2023 | 52.93 | 39.95 | 61.68 | 0.17 |
Current | |
Market Cap (M Riyal) | 685.60 |
Enterprise Value (EV) (M) | 694.74 |
Shares Outstanding ((M)) | 40.00 |
Book Value (BV) ( Riyal) | 1.68 |
Par Value ( Riyal) | 1.00 |
Adjusted P/E (Last12) | 29.16 |
Price/book | 10.20 |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: